Stock Analiz

Enveric Biosciences, Inc. ENVB

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.51Market cap $7M
Open the interactive analysis →

Enveric Biosciences, Inc. (ENVB) is a healthcare company listed in the US with a market value of about $7M.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: a 5-year average ROIC of -346%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 7% above the current price.

About Enveric Biosciences

Enveric Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $36M in 2016 to $40M in 2019, growth of about 3.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 4067% over three years (dilution for shareholders).

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+7%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)—
ROIC (5-yr avg.)-345.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue——————$40M$43M$49M$36M
Net income-$9M-$10M-$17M-$18M-$49M-$7M-$2M-$17M-$9M-$3M
Free cash flow——-$14M-$18M-$12M—-$732191-$3M-$3M-$3M
EPS (diluted)$-36.24$-228.48$-1455.49$-2340.01$-372.60$-214.20$-509.40$-3684.62$-3375.02$-945.00
Net margin——————-6.0%-39.3%-18.7%-7.7%
ROIC-165.9%-477.7%-664.2%-172.2%-249.5%-129.9%-54.0%-1805.2%-40.4%-31.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Enveric Biosciences stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 7% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Enveric Biosciences pay a dividend?

Not currently.

Is Enveric Biosciences a good stock to buy?

We do not give buy or sell advice. Enveric Biosciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.